Expensive processed meals and fatty, chemical-laden treats are highly profitable, as a trip to any supermarket, where they ...

Fatty pancreas disease, characterized by intra-pancreatic fat deposition, is more prevalent than diabetes, pancreatitis, and ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Physicians need to meet patients ‘where they are’ to develop a comprehensive plan to keep weight off and live a healthy ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Uncovering the full impact of dietary protein on human health is of prime importance, with potential to improve not only our ...

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro, have gained significant attention for their effectiveness in managing Type 2 diabetes and promoting weight loss. These medications work ...